• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting

by | Jun 6, 2024 | Publications

Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05835-4. Online ahead of print. NO ABSTRACT PMID:38839622 | DOI:10.1007/s00277-024-05835-4

Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)”

by | Jun 5, 2024 | Publications

Am J Hematol. 2024 Jun 4. doi: 10.1002/ajh.27406. Online ahead of print. NO ABSTRACT PMID:38837272 | DOI:10.1002/ajh.27406

The efficacy of Bortezomib-based regimens on survival state in newly diagnosed multiple myeloma patients

by | Jun 5, 2024 | Publications

Cell Mol Biol (Noisy-le-grand). 2024 Jun 5;70(6):164-176. doi: 10.14715/cmb/2024.70.6.25. ABSTRACT The prognosis of patients with multiple myeloma (MM) has significantly improved over the past ten years because of several innovative treatments, including the...

Imaging finding of multiple myeloma presenting as soft-tissue disease mimicking extrapleural space tumors: A case report

by | Jun 5, 2024 | Publications

Acta Radiol Open. 2024 Jun 3;13(6):20584601241246105. doi: 10.1177/20584601241246105. eCollection 2024 Jun. ABSTRACT Extramedullary involvement of multiple myeloma is an uncommon and aggressive condition characterized by proliferation of monoclonal plasma cells...

Do Spiritual Well-Being and Pain Intensity Predict Physical or Mental Components of Health-Related Quality-of-Life Scale in Patients With Multiple Myeloma?

by | Jun 5, 2024 | Publications

Pain Manag Nurs. 2024 Jun 3:S1524-9042(24)00164-4. doi: 10.1016/j.pmn.2024.05.006. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma is a complex disease and supportive care is important for improving quality of life. Management of disease treatment...

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience

by | Jun 5, 2024 | Publications

Transplant Cell Ther. 2024 Jun 2:S2666-6367(24)00437-8. doi: 10.1016/j.jtct.2024.05.025. Online ahead of print. ABSTRACT BACKGROUND: Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed-refractory multiple myeloma (RRMM). The aim of this study...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT